Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Dora Pinto(Vir Biotechnology (Switzerland)), Young‐Jun Park(University of Washington), Martina Beltramello(Vir Biotechnology (Switzerland)), Alexandra C. Walls(University of Washington), M. Alejandra Tortorici(Centre National de la Recherche Scientifique), Siro Bianchi(Vir Biotechnology (Switzerland)), Stefano Jaconi(Vir Biotechnology (Switzerland)), Katja Culap(Vir Biotechnology (Switzerland)), Fabrizia Zatta(Vir Biotechnology (Switzerland)), Anna De Marco(Vir Biotechnology (Switzerland)), Alessia Peter(Vir Biotechnology (Switzerland)), Barbara Guarino(Vir Biotechnology (Switzerland)), Roberto Spreafico(VIR Biotechnology (United States)), Elisabetta Cameroni(Vir Biotechnology (Switzerland)), James Brett Case(Washington University in St. Louis), Rita E. Chen(Washington University in St. Louis), Colin Havenar‐Daughton(VIR Biotechnology (United States)), Gyorgy Snell(VIR Biotechnology (United States)), Amalio Telenti(VIR Biotechnology (United States)), Herbert W. Virgin(VIR Biotechnology (United States)), Antonio Lanzavecchia(Vir Biotechnology (Switzerland)), Michael Diamond(Washington University in St. Louis), Katja Fink(Vir Biotechnology (Switzerland)), David Veesler(University of Washington), Davide Corti(Vir Biotechnology (Switzerland))
Cited by 2,140Open Access